Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

Investigational New Drugs

Volumn 23, Issue 3, 2005, Pages 243-251

  Mendez M ^a   Alfonso, P G ^b   Pujol, E ^c   Gonzalez E ^d   Castanon C ^e   Cerezuela, P ^f   Lopez Mateos Y ^g   Cruz, J J ^h  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e Hospital Virgen Blanca   (Spain)

^f Hosp Naval del Mediterráneo   (Spain)

^g HOSPITAL VIRGEN DEL PUERTO   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Colorectal cancer; CPT 11; Elderly; Tegafur; Uracil

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEGAFUR; UFT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC SYMPTOM; COLIC; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEFECATION DISORDER; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL RATE; TENESMUS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; TEGAFUR; URACIL;

EID: 18844403148     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-6733-0     Document Type: Article

References (44)

1. Coutinho AK, Rocha Lima CM: Metastatic colorectal cancer: Systemic treatment in the new millennium. Cancer Control 10(3): 224-238, 2003
2. Schmoll HJ, Buchele T, Grothey A, Dempke W: Where do we stand with 5-fluorouracil? Semin Oncol 26(6): 589-605, 1999
3. Bleiberg H, Hendlisz A: Advanced colorectal cancer treatment in Europe: What have we achieved? Anticancer Drugs 13(5): 461-471, 2002
4. Firvida JL, Irigoyen A, Vazquez-Estevez S, Diz P, Constenla M, Casal-Rubio J, Valladares-Ayerbes M, Castellanos J, Rodriguez R, Balcells M: Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91(4): 704-711, 2001
5. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14(3): 709-715, 1996
6. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15(1): 251-260, 1997
7. Douillard JY, Cunningham D, Roth AD, Navairo M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355(9209): 1041-1047, 2000
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): 905-914, 2000
9. Moehler M, Hoffmann T, Zanke C, Hohl H, Burg H, Ehscheid P, Schwindt P, Adami B, Schroeder M, Klein O, Baldus M, Galle PR, Heike M: Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs 14(1): 79-85, 2003
10. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulias V: Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: A multicenter phase II study. Am J Clin Oncol 25(1): 65-70, 2002
11. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL: Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist 6(1): 81-91, 2001
12. Meta-Analysis Group In Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16(11): 3537-3541, 1998
13. Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1): 301-308, 1998
14. Bleiberg H, Di Leo A: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. J Clin Oncol 20(4): 1145-1146, 2002
15. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345(2): 144-145; discussion 146, 2001
16. Malet-Martino M, Jolimaitre P, Martino R: The prodrugs of 5-fluorouracil. Curr Med Chem Anti-Cane Agents 2(2): 267-310, 2002
17. Fujii S, Kitano S, Ikenaka K, Shirasaka T: Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70(2): 209-214, 1979
18. Alonso V, Escudero P, Grandez R, Alvarez I, Ruiz de Lobera A, Polo E, Corral M, Lara R, Puertolas T, Anton A: Weekly irinotecan (CPT-11) combined with uracil-tegafur (UFT) as first line treatment for metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 22(335 (abstract 1344), 2003
19. Sulkes A, Benner SE, Canetta RM: Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16(10): 3461-3475, 1998
20. Sun W, Haller D: UFT in the treatment of colorectal and breast cancer. Oncology (Huntingt) 15(1 Suppl 2): 49-56, 2001
21. Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M, Creaven PJ: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37(6): 581-586, 1996
22. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr., Markowitz AB, Abbruzzese JL, Bready B: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12(11): 2296-2300, 1994
23. Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez-Martinez B, Blanco E, Garcia-Giron C, Juarez F, Garrido P: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31A(13/14): 2215-2219, 1995
24. Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J: Uracil and tegafur modulated with leucovorin: An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer 79(10): 1884-1889, 1997
25. Abad A, Navarro M, Sastre J, Marcuello E, Aranda E, Gallen M, Fernandez-Martos C, Martin C, Diaz-Rubio E: A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology (Huntingt) 11(9 Suppl 10): 53-57, 1997
26. Yang TS, Wang JY, Tang R, Hsu KC, Chen JS: Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. Jpn J Clin Oncol 32(9): 352-357, 2002
27. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP: A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75(3): 782-785, 1995
28. Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D: Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 43(3): 221-226, 1999
29. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20(17): 3605-3616, 2002
30. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20(17): 3617-3627, 2002
31. Ducreux M, Kohne CH, Schwartz GK, Vanhoefer U: Irinotecan in metastatic colorectal cancer: Dose intensification and combination with new agents, including biological response modifiers. Ann Oncol 14 (Suppl 2): 17-23, 2003
32. Oral tegafur-uracil plus leucovorin in metastatic colorectal cancer: Clinical insights. Proceedings of a roundtable expert meeting. October 2002, Nice, France. Anticancer Drugs 14 (Suppl 2): S1-10, 2003
33. Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D: A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 14(8): 1264-1269, 2003
34. Alonso V, Escudero P, Zorrilla M, Isla MD, Herrero A. Mayordomo JI, Martinez-Trufero J, Saenz A, Tres A, Anton A: Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur J Cancer 37(18): 2385-2391, 2001
35. Dufour PR, Madueno R, Senesse P, Kurtz JE, Tonelli D, Ychou M: Phase I dose escalation study of the combination of oral uft/leucovorin (LV) with irinotecan (CPT-11) in patients (pts) with advanced or metastatic colorectal cancer (CRC) previously untreated with chemotherapy for metastatic disease. Proc Am Soc Clin Oncol 22(317): (abstract 1273), 2003
36. Cruz JJ, Méndez M, Pujol E, Belón J, Cerezuela P: Weekly Irinotecan (CPT-11) in Combination with Oral Uracil and Ftorafur (UFT) Plus Folinic Acid (FA) as First Line Treatment in Advanced Colorectal Cancer (CRC). Preliminary Results. Proc Am Soc Clin Oncol 20(Abstract 2186), 2001
37. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981
38. Guidelines for the reporting of adverse drug reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute, 1988
39. Thall PF, Simon R, Ellenberg SS: A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45(2): 537-547, 1989
40. Escudero MP, Alonso V, Puertolas T, Alvarez I, Corral M, Herrero A, Andres A, Martinez-Trufero J, Filipovich E, Grandez R, Artal A, Anton A, Tres A, Polo E: Weekly irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma (ACRC). Proc Am Soc Clin Oncol: Abstract 2238, 2002
41. Ikeda M, Seshimo I, Takayama O, Yasui M, Fukunaga H, Ikenaga M, Yamamoto H, Ohue M, Sekimoto M, Monden M: A phase II study of the safety, pharmacokinetics and efficacy of CPT-11 combined with uracil/tegafur (UFT) in patients with unresectable colorectal cancer (CRC). Proc Am Soc Clin Oncol 22(327): (abstract 1312), 2003
42. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138): 1413-1418, 1998
43. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138): 1407-1412, 1998
44. Diaz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallen M, Marcuello E, Rifa J, Massuti T, Cervantes A, Anton A, Fernandez Martos C: UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Huntingt) 13(7 Suppl 3): 35-40, 1999